(Atorvastatin + ezetimibe) is under clinical development by Addpharma and currently in Phase III for Hypercholesterolemia. According to GlobalData, Phase III drugs for Hypercholesterolemia have a 55% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how (Atorvastatin + ezetimibe)’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
(Atorvastatin + ezetimibe) overview
Atorvastation in combination with ezetimibe is under development for the treatment of primary hypercholesterolemia and hyperlipidemia. It is an incrementally modified drug (IMD). It is administered through oral route. Atorvastatin targets HMG-CoA reductase and ezetimibe targets Niemann-Pick C1-like protein 1.
Addpharma is a specialized pharmaceutical company that develops medicinal novel drugs including complexes, release controlling agents, and absorption improving agents. Addpharma is headquartered in Yongin, South Korea.
For a complete picture of (Atorvastatin + ezetimibe)’s drug-specific PTSR and LoA scores, buy the report here.